Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bictegravir/lenacapavir in children and adolescents with HIV-1
2023-509428-16-00Phase 3Authorised
- Sponsor
- Gilead Sciences
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, open-label trial of bictegravir and lenacapavir in Human immunodeficiency virus infection type 1 (3 cohorts), sponsored by Gilead Sciences. Primary endpoints: Steady-state PK parameters of bictegravir and lenacapavir, Treatment-emergent adverse events through Week 24 and 1 more. Planned start Sep 2024; status: authorised.
02
Drugs
bictegravirlenacapavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2023-509428-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509428-16-00.